1. A class action lawsuit is ongoing against Biohaven Ltd. (BHVN). 2. Investors allege misleading statements regarding drug candidates during specific dates. 3. The lawsuit claims inflated efficacy and regulatory prospects of treatments. 4. Affected investors are encouraged to join the class action before September 12, 2025. 5. The class action has not yet been certified.
The class action lawsuit indicates potential legal risks, impacting investor confidence, similar to past fraud allegations against firms which usually lead to share price declines.
Legal challenges like this can have significant impacts on stock performance and investor sentiment due to perceived instability.
Immediate stock price reactions to bad news are common, affecting investor sentiment until resolution or class certification.
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 24, 2023 and May 14, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 12, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Biohaven, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bhvn-investors-have-opportunity-to-lead-biohaven-ltd-securities-fraud-lawsuit-with-the-schall-law-firm-302543396.html
SOURCE The Schall Law Firm